Biogen Bounces Back With FDA Nod for High-Dose Spinal Muscular Atrophy Drug Leave a Comment / By Leonardo Arias / 30/03/2026 The FDA rejected the high-dose regimen of Spinraza in September last year due to manufacturing concerns.
